nach oben

Erschienen in:

06.11.2019 | Original Investigation

A new multi-epitope peptide vaccine induces immune responses and protection against Leishmania infantum in BALB/c mice

verfasst von: Bahareh Vakili, Navid Nezafat, Bijan Zare, Nasrollah Erfani, Maryam Akbari, Younes Ghasemi, Mohammad Reza Rahbar, Gholam Reza Hatam

Erschienen in: Medical Microbiology and Immunology | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Visceral leishmaniasis (VL) is a tropical and subtropical disease which is endemic in more than eighty countries around the world. Leishmania infantum is one of the main causative agents of VL disease. Currently, there is no approved-to-market vaccine for VL therapy. In this study, we evaluated cellular and humoral immune responses induced by our newly designed multi-epitope vaccine in BALB/c mice. Four antigenic proteins, including histone H1, sterol 24-c-methyltransferase (SMT), Leishmania-specific hypothetical protein (LiHy), and Leishmania-specific antigenic protein (LSAP) were chosen for the prediction of potential immunodominant epitopes. Moreover, to enhance vaccine immunogenicity, two toll-like receptors 4 (TLR4) agonists, resuscitation-promoting factors of Mycobacterium tuberculosis (RpfE and RpfB), were employed as the built-in adjuvants. Immunization with the designed multi-epitope vaccine elicited a robust Th1-type immune response, compared to other groups, as shown by increased levels of IL-2, IFN-γ, TNF-α, and IgG2a. Furthermore, a significant decrease was observed in Th-2-type-related cytokines such as IL-4 in immunized mice. The designed construct also induced a significant reduction in parasite load (p < 0.0001), conferring protection against L. infantum challenge. This study could be promising in gaining insight towards the potential of peptide epitope-based vaccines as effective protective approaches against Leishmania species.

Nur mit Berechtigung zugänglich

Steverding D (2017) The history of leishmaniasis. Parasite Vector 10(1):82. https://doi.org/10.1186/s13071-017-2028-5 CrossRef

Rogers ME (2012) The role of leishmania proteophosphoglycans in sand fly transmission and infection of the Mammalian host. Front Microbiol 3:223–223. https://doi.org/10.3389/fmicb.2012.00223 CrossRefPubMedPubMedCentral

Bates PA (2007) Transmission of Leishmania metacyclic promastigotes by phlebotomine sand flies. Int J Parasitol 37(10–3):1097–1106. https://doi.org/10.1016/j.ijpara.2007.04.003 CrossRefPubMedPubMedCentral

Kuhls K, Alam MZ, Cupolillo E, Ferreira GEM, Mauricio IL, Oddone R, Feliciangeli MD, Wirth T, Miles MA, Schönian G (2011) Comparative microsatellite typing of new world Leishmania infantum reveals low heterogeneity among populations and its recent old world origin. PLoS Negl Trop Dis 5(6):e1155. https://doi.org/10.1371/journal.pntd.0001155 CrossRefPubMedPubMedCentral

Ready PD (2014) Epidemiology of visceral leishmaniasis. J Clin Epidemiol 6:147–154. https://doi.org/10.2147/CLEP.S44267 CrossRef

Nagle AS, Khare S, Kumar AB, Supek F, Buchynskyy A, Mathison CJN, Chennamaneni NK, Pendem N, Buckner FS, Gelb MH, Molteni V (2014) recent developments in drug discovery for Leishmaniasis and human African Trypanosomiasis. Chem Rev 114(22):11305–11347. https://doi.org/10.1021/cr500365f CrossRefPubMedPubMedCentral

Oryan A (2015) Plant-derived compounds in treatment of leishmaniasis. IJVR 16(1):1–19PubMedPubMedCentral

Freitas-Junior LH, Chatelain E, Kim HA, Siqueira-Neto JL (2012) Visceral leishmaniasis treatment: what do we have, what do we need and how to deliver it? Int J Parasitol 2:11–19. https://doi.org/10.1016/j.ijpddr.2012.01.003 CrossRef

Singh N, Kumar M, Singh RK (2012) Leishmaniasis: current status of available drugs and new potential drug targets. Asian Pac J Trop Dis 5(6):485–497. https://doi.org/10.1016/S1995-7645(12)60084-4 CrossRef

10.

Hefnawy A, Berg M, Dujardin J-C, De Muylder G (2017) Exploiting knowledge on Leishmania drug resistance to support the quest for new drugs. Trends Parasitol 33(3):162–174. https://doi.org/10.1016/j.pt.2016.11.003 CrossRefPubMed

11.

Ponte-Sucre A, Gamarro F, Dujardin JC, Barrett MP, Lopez-Velez R, Garcia-Hernandez R, Pountain AW, Mwenechanya R, Papadopoulou B (2017) Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. PLoS Negl Trop Dis 11(12):e0006052. https://doi.org/10.1371/journal.pntd.0006052 CrossRefPubMedPubMedCentral

12.

Evans KJ, Kedzierski L (2012) Development of vaccines against visceral Leishmaniasis. J Trop Med 2012:892817. https://doi.org/10.1155/2012/892817 CrossRefPubMed

13.

Nascimento IP, Leite LCC (2012) Recombinant vaccines and the development of new vaccine strategies. Braz J Med Biol Rre 45(12):1102–1111. https://doi.org/10.1590/S0100-879X2012007500142 CrossRef

14.

Akbari M, Oryan A, Hatam G (2017) Application of nanotechnology in treatment of leishmaniasis: a review. Acta Trop 172:86–90. https://doi.org/10.1016/j.actatropica.2017.04.029 CrossRefPubMed

15.

Ghorbani M, Farhoudi R (2018) Leishmaniasis in humans: drug or vaccine therapy? Drug Des Dev Ther 12:25–40. https://doi.org/10.2147/DDDT.S146521 CrossRef

16.

Almeida A, Machado LFM, Doro D, Nascimento FC, Damasceno L, Gazzinelli RT, Fernandes AP, Junqueira C (2018) New vaccine formulations containing a modified version of the amastigote 2 antigen and the non-virulent Trypanosoma cruzi CL-14 strain are highly antigenic and protective against Leishmania infantum challenge. Front Immunol 9:465. https://doi.org/10.3389/fimmu.2018.00465 CrossRefPubMedPubMedCentral

17.

Chávez-Fumagalli MA, Costa MA, Oliveira DM, Ramírez L, Costa LE, Duarte MC (2010) Vaccination with the Leishmania infantum ribosomal proteins induces protection in BALB/c mice against Leishmania chagasi and Leishmania amazonensis challenge. Microbes Infect 12(12–13):967–977. https://doi.org/10.1016/j.micinf.2010.06.008 CrossRefPubMed

18.

Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG (2007) Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4 + T cells. Infect Immun 75:(9)4648–4654. https://doi.org/10.1128/IAI.00394-07 CrossRefPubMedPubMedCentral

19.

Rodrigues V, Cordeiro-Da-Silva A, Laforge M, Silvestre R, Estaquier J (2016) Regulation of immunity during visceral Leishmania infection. Parasite Vector 9(1):118. https://doi.org/10.1186/s13071-016-1412-x CrossRef

20.

Khadem F, Uzonna JE (2014) Immunity to visceral leishmaniasis: implications for immunotherapy. Future Microbiol 9(7):901–915. https://doi.org/10.2217/fmb.14.43 CrossRefPubMed

21.

Bretscher PA (2014) On the mechanism determining the Th1/Th2 phenotype of an immune response, and its pertinence to strategies for the prevention, and treatment, of certain infectious diseases. Scand J Immunol 79(6):361–376. https://doi.org/10.1111/sji.12175 CrossRefPubMedPubMedCentral

22.

Mendonça SCF (2016) Differences in immune responses against Leishmania induced by infection and by immunization with killed parasite antigen: implications for vaccine discovery. Parasite Vector 9(1):492. https://doi.org/10.1186/s13071-016-1777-x CrossRef

23.

Nezafat N, Eslami M, Negahdaripour M, Rahbar MR, Ghasemi Y (2017) Designing an efficient multi-epitope oral vaccine against Helicobacter pylori using immunoinformatics and structural vaccinology approaches. Mol BioSyst 13(4):699–713. https://doi.org/10.1039/c6mb00772d CrossRefPubMed

24.

Validi M, Karkhah A, Prajapati VK, Nouri HR (2018) Immuno-informatics based approaches to design a novel multi epitope-based vaccine for immune response reinforcement against Leptospirosis. Mol Immunol 104:128–138. https://doi.org/10.1016/j.molimm.2018.11.005 CrossRefPubMed

25.

Molero-Abraham M, Lafuente EM, Flower DR, Reche PA (2013) Selection of conserved epitopes from hepatitis C virus for pan-populational stimulation of T-cell responses. Clin Dev Immunol 2013(2013):601943. https://doi.org/10.1155/2013/601943 CrossRefPubMedPubMedCentral

26.

Solanki V, Tiwari V (2018) Subtractive proteomics to identify novel drug targets and reverse vaccinology for the development of chimeric vaccine against Acinetobacter baumannii. Sci Rep 8(1):9044. https://doi.org/10.1038/s41598-018-26689-7 CrossRefPubMedPubMedCentral

27.

Vakili B, Eslami M, Hatam GR, Zare B, Erfani N, Nezafat N, Ghasemi Y (2018) Immunoinformatics-aided design of a potential multi-epitope peptide vaccine against Leishmania infantum. Int J Biol Macromol 120:1127–1139. https://doi.org/10.1016/j.ijbiomac.2018.08.125 CrossRefPubMed

28.

Vakili B, Nezafat N, Hatam GR, Zare B, Erfani N, Ghasemi Y (2018) Proteome-scale identification of Leishmania infantum for novel vaccine candidates: a hierarchical subtractive approach. Comput Biol Chem 72:16–25. https://doi.org/10.1016/j.compbiolchem.2017.12.008 CrossRefPubMed

29.

Agallou M, Margaroni M, Athanasiou E, Toubanaki DK, Kontonikola K, Karidi K, Kammona O, Kiparissides C, Karagouni E (2017) Identification of BALB/c immune markers correlated with a partial protection to Leishmania infantum after vaccination with a rationally designed multi-epitope cysteine protease a peptide-based nanovaccine. PLoS Negl Trop Dis 11(1):e0005311. https://doi.org/10.1371/journal.pntd.0005311 CrossRefPubMedPubMedCentral

30.

Dasgupta S, Aghazadeh-Dibavar S, Bandyopadyay M (2014) The role of toll-like receptor agonists in the immunotherapy of leishmaniosis. An update and proposal for a new form of anti-leishmanial therapy. Ann Parasitol 60(2):75–82PubMed

31.

Aathmanathan VS, Jothi N, Prajapati VK, Krishnan M (2018) Investigation of immunogenic properties of Hemolin from silkworm, Bombyx mori as carrier protein: an immunoinformatic approach. Sci Rep 8(1):6957. https://doi.org/10.1038/s41598-018-25374-z CrossRefPubMedPubMedCentral

32.

Reed SG, Coler RN, Mondal D, Kamhawi S, Valenzuela JG (2016) Leishmania vaccine development: exploiting the host-vector-parasite interface. Expert Rev Vaccines 15(1):81–90. https://doi.org/10.1586/14760584.2016.1105135 CrossRefPubMed

33.

De Brito RCF, Cardoso JMDO, Reis LES, Vieira JF, Mathias FAS, Roatt BM, Aguiar-Soares RDDO, Ruiz JC, Resende DDM, Reis AB (2018) Peptide vaccines for Leishmaniasis. Front Immunol 9(1043):1–11. https://doi.org/10.3389/fimmu.2018.01043 CrossRef

34.

Hos BJ, Tondini E, Van Kasteren SI, Ossendorp F (2018) Approaches to improve chemically defined synthetic peptide vaccines. Front Immunol 9:884–884. https://doi.org/10.3389/fimmu.2018.00884 CrossRefPubMedPubMedCentral

35.

Rueckert C, Guzmán CA (2012) Vaccines: from empirical development to rational design. PLoS Pathog 8(11):e1003001. https://doi.org/10.1371/journal.ppat.1003001 CrossRefPubMedPubMedCentral

36.

Goto Y, Bogatzki LY, Bertholet S, Coler RN, Reed SG (2007) Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant. Vaccine 25(42):7450–7458. https://doi.org/10.1016/j.vaccine.2007.08.001 CrossRefPubMedPubMedCentral

37.

Li W, Joshi MD, Singhania S, Ramsey KH, Murthy AK (2014) Peptide vaccine: progress and challenges. Vaccines 2(3):515–536. https://doi.org/10.3390/vaccines2030515 CrossRefPubMedPubMedCentral

38.

Coelho EA, Tavares CAP, Carvalho FAA, Chaves KF, Teixeira KN, Rodrigues RC (2003) Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection. Infect Immun 71(7):3988–3994. https://doi.org/10.1128/iai.71.7.3988-3994.2003 CrossRefPubMedPubMedCentral

39.

Mizbani A, Taheri T, Zahedifard F, Taslimi Y, Azizi H, Azadmanesh K, Papadopoulou B, Rafati S (2009) Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. Vaccine 28(1):53–62. https://doi.org/10.1016/j.vaccine.2009.09 CrossRefPubMed

40.

Resende DM, Caetano BC, Dutra MS, Penido ML, Abrantes CF, Verly RM, Resende JM, Piló-Veloso D, Rezende SA, Bruna-Romero O (2008) Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-γ and cytolytic activity by CD8⁺ T cells. Vaccine 26(35):4585–4593. https://doi.org/10.1016/j.vaccine.2008.05.091 CrossRefPubMed

41.

Regina-Silva S, Feres AMLT, França-Silva JC, Dias ES, Michalsky ÉM, De Andrade HM, Coelho EAF, Ribeiro GM, Fernandes AP, Machado-Coelho GLL (2016) Field randomized trial to evaluate the efficacy of the Leish-Tec^® vaccine against canine visceral leishmaniasis in an endemic area of Brazil. Vaccine 34(19):2233–2239. https://doi.org/10.1016/j.vaccine.2016.03.019 CrossRefPubMed

42.

Ghedin E, Zhang WW, Charest H, Sundar S, Kenney RT, Matlashewski G (1997) Antibody response against a Leishmania donovani amastigote-stage-specific protein in patients with visceral leishmaniasis. Clin Diagn Lab Immunol 4(5):530–535CrossRefPubMedPubMedCentral

43.

Bhatia A, Daifalla NS, Jen S, Badaro R, Reed SG, Skeiky YA (1999) Cloning, characterization and serological evaluation of K9 and K26: two related hydrophilic antigens of Leishmania chagasi. Mol Biochem Parasitol 102(2):249–261CrossRefPubMed

44.

Doherty DG, Melo AM, Moreno-Olivera A, Solomos AC (2018) Activation and regulation of B cell responses by invariant natural killer T Cells. Front Immunol 9:1360. https://doi.org/10.3389/fimmu.2018.01360 CrossRefPubMedPubMedCentral

45.

Kaiko GE, Horvat JC, Beagley KW, Hansbro PM (2008) Immunological decision-making: how does the immune system decide to mount a helper T-cell response? Immunology 123(3):326–338. https://doi.org/10.1111/j.1365-2567.2007.02719.x CrossRefPubMedPubMedCentral

46.

Alexander J, Brombacher F (2012) T helper1/t helper2 cells and resistance/susceptibility to leishmania infection: is this paradigm still relevant? Front Immunol 3:80–80. https://doi.org/10.3389/fimmu.2012.00080 CrossRefPubMedPubMedCentral

47.

Iborra S, Carrión J, Anderson C, Alonso C, Sacks D, Soto M (2005) Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice. Infect Immun 73(9):5842–5852. https://doi.org/10.1128/IAI.73.9.5842-5852.2005 CrossRefPubMedPubMedCentral

48.

Solano-Gallego L, Montserrat-Sangrà S, Ordeix L, Martínez-Orellana P (2016) Leishmania infantum-specific production of IFN-γ and IL-10 in stimulated blood from dogs with clinical leishmaniosis. Parasite Vector 9(1):317. https://doi.org/10.1186/s13071-016-1598-y CrossRef

49.

Wang Z-E, Reiner SL, Zheng S, Dalton DK, Locksley RM (1994) CD4⁺ effector cells default to the Th2 pathway in interferon gamma-deficient mice infected with Leishmania major. J Exp Med 179(4):1367–1371CrossRefPubMed

50.

Gannavaram S, Bhattacharya P, Ismail N, Kaul A, Singh R, Nakhasi HL (2016) Modulation of innate immune mechanisms to enhance Leishmania vaccine-induced immunity: role of coinhibitory molecules. Front Immunol 13(7):187. https://doi.org/10.3389/fimmu.2016.00187 CrossRef

51.

Gupta G, Oghumu S, Satoskar AR (2013) Mechanisms of immune evasion in leishmaniasis. Adv Appl Microbiol 82:155–184. https://doi.org/10.1016/B978-0-12-407679-2.00005-3 CrossRefPubMedPubMedCentral

52.

Liew F, Parkinson C, Millott S, Severn A, Carrier M (1990) Tumour necrosis factor (TNF alpha) in leishmaniasis. I. TNF alpha mediates host protection against cutaneous leishmaniasis. Immunology 69(4):570PubMedPubMedCentral

53.

Sjölander A, Baldwin TM, Curtis JM, Handman E (1998) Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis. J Immunol 160(8):3949–3957PubMed

54.

Basu R, Bhaumik S, Basu JM, Naskar K, De T, Roy S (2005) Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and-resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1-and Th2-like responses in visceral leishmaniasis. J Immunol 174(11):7160–7171. https://doi.org/10.4049/jimmunol.174.11.7160 CrossRefPubMed

55.

Roberts MT, Stober CB, Mckenzie AN, Blackwell JM (2005) Interleukin-4 (IL-4) and IL-10 collude in vaccine failure for novel exacerbatory antigens in murine Leishmania major infection. Infect Immun 73(11):7620–7628CrossRefPubMedPubMedCentral

56.

Hurdayal R, Brombacher F (2014) The role of IL-4 and IL-13 in cutaneous Leishmaniasis. Immunol Lett 161(2):179–183. https://doi.org/10.1016/j.imlet.2013.12.022 CrossRefPubMed

57.

Murphy ML, Wille U, Villegas EN, Hunter CA, Farrell JP (2001) IL-10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol 31(10):2848–2856CrossRefPubMed

58.

Mcgeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, Mcclanahan T, Cua DJ (2007) TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 8(12):1390–1397. https://doi.org/10.1038/ni1539 CrossRefPubMed

59.

Biedermann T, Zimmermann S, Himmelrich H, Gumy A, Egeter O, Sakrauski AK, Seegmuller I, Voigt H, Launois P, Levine AD, Wagner H, Heeg K, Louis JA, Rocken M (2001) IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat Immunol 2(11):1054–1060. https://doi.org/10.1038/ni725 CrossRefPubMed

60.

Vouldoukis I, Becherel PA, Riveros-Moreno V, Arock M, Da Silva O, Debre P, Mazier D, Mossalayi MD (1997) Interleukin-10 and interleukin-4 inhibit intracellular killing of Leishmania infantum and Leishmania major by human macrophages by decreasing nitric oxide generation. Eur J Immunol 27(4):860–865. https://doi.org/10.1002/eji.1830270409 CrossRefPubMed

61.

Nylén S, Gautam S (2010) Immunological perspectives of leishmaniasis. J Glob Infect Dis 2(2):135–146. https://doi.org/10.4103/0974-777X.62876 CrossRefPubMedPubMedCentral

62.

Ghosh A, Zhang WW, Matlashewski G (2001) Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 20(1–2):59–66CrossRefPubMed

63.

Darabi H, Eravani D, Sanos S, Kaye P, Taghikhani M, Jamshidi S (2005) Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 23(28):3716–3725CrossRefPubMed

64.

Rafati S, Zahedifard F, Nazgouee F (2006) Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 24(12):2169–2175CrossRefPubMed

65.

Mutiso JM, Macharia JC, Gicheru MM (2010) A review of adjuvants for Leishmania vaccine candidates. Biomed Res 24(1):16–25. https://doi.org/10.1016/S1674-8301(10)60004-8 CrossRef

66.

Gnjatic S, Sawhney NB, Bhardwaj N (2010) Toll-like receptor agonists: are they good adjuvants? Cancer J (Sudbury, Mass) 16(4):382–391. https://doi.org/10.1097/PPO.0b013e3181eaca65 CrossRef

67.

Li Q, Guo Z (2018) Recent advances in toll like receptor-targeting glycoconjugate vaccines. Molecules. https://doi.org/10.3390/molecules23071583 CrossRefPubMedPubMedCentral

68.

Reed SG, Hsu F-C, Carter D, Orr MT (2016) The science of vaccine adjuvants: advances in TLR4 ligand adjuvants. Curr Opin Immunol 41:85–90CrossRefPubMed

69.

Kim JS, Kim WS, Choi HG, Jang B, Lee K, Park JH, Kim HJ, Cho SN, Shin SJ (2013) Mycobacterium tuberculosis RpfB drives Th1-type T cell immunity via a TLR4-dependent activation of dendritic cells. J Leukoc Biol 94(4):733–749. https://doi.org/10.1189/jlb.0912435 CrossRefPubMed

70.

Choi HG, Kim WS, Back YW, Kim H, Kwon KW, Kim JS, Shin SJ, Kim HJ (2015) Mycobacterium tuberculosis RpfE promotes simultaneous Th1- and Th17-type T-cell immunity via TLR4-dependent maturation of dendritic cells. Eur J Immunol 45(7):1957–1971. https://doi.org/10.1002/eji.201445329 CrossRefPubMed

Titel: A new multi-epitope peptide vaccine induces immune responses and protection against Leishmania infantum in BALB/c mice
verfasst von: Bahareh Vakili
Navid Nezafat
Bijan Zare
Nasrollah Erfani
Maryam Akbari
Younes Ghasemi
Mohammad Reza Rahbar
Gholam Reza Hatam
Publikationsdatum: 06.11.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Medical Microbiology and Immunology / Ausgabe 1/2020
Print ISSN: 0300-8584
Elektronische ISSN: 1432-1831
DOI: https://doi.org/10.1007/s00430-019-00640-7

Paracoccidioides species present distinct fungal adherence to epithelial lung cells and promote different IL-8 secretion levels

Original Investigation

Comparative in vitro activity of bacteriophage endolysin HY-133 against Staphylococcus aureus attached to vascular graft surface

Original Investigation

Caenorhabditis elegans as a model animal for investigating fungal pathogenesis

Review

Association of NFκB and related-cytokines with the viral load and development of antibodies against HHV-8 in people living with HIV/AIDS

Original Investigation

Characterization of a novel Helicobacter pylori East Asian-type CagA ELISA for detecting patients infected with various cagA genotypes

Original Investigation

An investigation of the utility of plasma Cytomegalovirus (CMV) microRNA detection to predict CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients

Original Invesigation

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Studie zur HIFU bei Prostatakrebs lässt viele Fragen offen

22.01.2025
Prostatakarzinom
Nachrichten

Führt eine HIFU-Ablation beim Prostatakarzinom im Vergleich mit einer radikalen Prostatektomie zu ähnlichen onkologischen, aber besseren funktionalen Ergebnissen? Interimsdaten der französischen HIFI-Studie sind uneindeutig. In einem Kommentar zur Studie werden zumindest drei allgemeine Erkenntnisse herausgearbeitet.

Leitlinienkonformes Management thermischer Verletzungen

22.01.2025
Verbrennung
Nachrichten

Thermische Verletzungen gehören zu den schwerwiegendsten Traumen und hinterlassen oft langfristige körperliche und psychische Spuren. Die aktuelle S2k-Leitlinie „Behandlung thermischer Verletzungen im Kindesalter (Verbrennung, Verbrühung)“ bietet eine strukturierte Übersicht über das empfohlene Vorgehen.

Frühe Hyperoxie nach Reanimation schlecht für die Prognose?

22.01.2025
Kardiopulmonale Reanimation
Nachrichten

Kommt es sehr früh nach einer kardiopulmonalen Reanimation zu einem Zustand der Hyperoxie, ist dies bei Patientinnen und Patienten nach einem Herzstillstand mit schlechteren funktionellen Ergebnissen assoziiert. Das zeigt eine Sekundäranalyse der TTM-2-Studie.

Infektanfälligkeit in früher Kindheit: eine bleibende Last?

22.01.2025
Pädiatrische Infektiologie
Nachrichten

Wenn Kinder in den ersten Lebensjahren immer wieder Infekte durchmachen, lässt dies Schlüsse auf die Infektneigung in der weiteren Kindheit zu.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

A new multi-epitope peptide vaccine induces immune responses and protection against Leishmania infantum in BALB/c mice

Abstract

Weitere Artikel der Ausgabe 1/2020

Paracoccidioides species present distinct fungal adherence to epithelial lung cells and promote different IL-8 secretion levels

Comparative in vitro activity of bacteriophage endolysin HY-133 against Staphylococcus aureus attached to vascular graft surface

Caenorhabditis elegans as a model animal for investigating fungal pathogenesis

Association of NFκB and related-cytokines with the viral load and development of antibodies against HHV-8 in people living with HIV/AIDS

Characterization of a novel Helicobacter pylori East Asian-type CagA ELISA for detecting patients infected with various cagA genotypes

An investigation of the utility of plasma Cytomegalovirus (CMV) microRNA detection to predict CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Neu im Fachgebiet Innere Medizin

Studie zur HIFU bei Prostatakrebs lässt viele Fragen offen

Leitlinienkonformes Management thermischer Verletzungen

Frühe Hyperoxie nach Reanimation schlecht für die Prognose?

Infektanfälligkeit in früher Kindheit: eine bleibende Last?

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten